No Data
Bo Pharm (02142) has submitted a new drug clinical trial application for the treatment of chronic obstructive pulmonary disease to the National Medical Products Administration.
Jingu News | Hubei Pharmaceuticals (02142) announced that the Group has submitted an application for a new drug clinical trial (IND) of HBM9378 (or SKB378, as described by Sichuan Kellon Biomedical Pharmaceutical Co., Ltd. (06990) and the Group's development partner of HBM9378) to the National Medical Products Administration. The drug is a fully human antibody targeting thymic stromal lymphopoietin ("TSLP"), used to treat chronic obstructive pulmonary disease ("COPD").
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
[Brokerage Focus] CMB International: Benefits from overseas interest rate cuts and domestic macroeconomic improvement. The pharmaceutical industry, as a high-elasticity sector, is expected to outperform the market.
Kingold Financial News | CICC International stated that benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the medical sector, as a high-elasticity industry, is expected to outperform the market. The bank believes that the performance of the macro economy is closely related to the income and expenses of medical insurance funds, as well as medical and health consumption. As the policy focus shifts to stimulating the economy, the bank believes that policies for updating medical devices are expected to accelerate implementation, and support policies for innovative drugs are also expected to be implemented locally. The CXO sector is expected to benefit from the recovery in overseas research and development demand, and the impact of the "Biosecurity Law" may be limited. A new round of domestic medical insurance negotiations is about to land. Although there is certain pressure on the income and expenses of medical insurance funds, the bank believes that medical insurance
Sinolink Securities: Pharmaceutical prosperity in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the healthcare sector, changes in the consumer environment, and some medical insurance cost control policies still being implemented, the business climate continued to bottom out in the Q3 report, with a slower rebound than expected.
Hong Kong stocks are moving | The morning trading of Coland Biotech-B (06990) surged more than 8% with the application for Laxusathuzumab monoklonal antibody new drug being accepted, there may be multiple products launched recently.
Hansoh Bio-B (06990) rose more than 8% in the morning, as of press time, up 5.65% to 187 Hong Kong dollars, with a turnover of 35.4396 million Hong Kong dollars.
Sichuan Kelun-Biotech Biopharmaceutical Engages Downstream Distributor; Seller
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}